Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01763034

Enrollment

200

Registered

2013-01-08

Start date

2013-02-28

Completion date

2014-03-31

Last updated

2013-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serum Creatinine Before and After Coronary Angiogram, Serum Cystatin C Before and After Coronary Angiogram

Brief summary

Contrast media induced nephropathy (CIN) is considered to be a serious complication in patient who underwent coronary angiogram (CAG). The pathogenesis of CIN does not well understood. The probable one is the contrast media makes the afferent vessel in glomeruli constrict and results in renal shut down. Limb ischemic preconditioning, a procedure that makes muscles become ischemic and adapt themselves to produce some cytokines for signaling the vessel more dilated. After the reperfusion, these cytokines are getting back to systemic circulation and effect the afferent vessel in glomeruli to become more dilated and prevent CIN.

Interventions

PROCEDURElimb ischemic preconditioning

use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diabetic kidney disease * Elective coronary angiogram * Glomerular filtration rate \< 60 ml/min by Cockroft-Gault or Modification of Diet in Renal Disease or CKD-EPI

Exclusion criteria

* Refuse or reject to inform consented * Hemodynamic compromise (Heart failure, need for intraaortic balloon pump) * Expose to drug or chemical substances potentially to be a nephrotoxic agent with in 1 mo (Not include preexisting Angiotensin converting enzyme inhibitor or Angiotensin receptor blocker with stable serum creatinine) * Documented or suspected of peripheral arterial disease, upper or lower limb * Bleeding diathesis * Contraindicated for coronary angiogram * currently on renal replacement therapy

Design outcomes

Primary

Measure	Time frame
kidney injury before and after coronary angiogram.	1 year

Countries

Thailand

Contacts

Primary ContactSIRAPAT POONVUTIKUL, MD

boybm027@hotmail.com66891038796

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026